Today's Highlights
In a year full of stellar submissions, it was no easy feat for the Awards Committees to select the winners. Congratulations to everyone who submitted work. The ISHLT2019 Award Winners are listed here! Read more
Isavuconazonium Pharmacokinetic Interactions with Immunosuppression in Thoracic Transplant Recipients
Carrie Burt, PharmD, MPH
Azole antifungals (e.g. voriconazole, posaconazole, itraconazole) are commonly used to prevent and treat fungal infections in the cardiothoracic transplant population. However, their use is complicated by their inhibition of cytochrome P450 (CYP) enzymes, particularly CYP3A4. This inhibition is clinically significant as it will interact with many of our workhorse immunosuppressive agents, particularly our calcineurin and mTOR inhibitors. This interaction can be profound and well documented and empiric adjustments to immunosuppressive doses are commonly recommended. Read more
Scleroderma: The Ability to Swallow is Optional
Maria Crespo, MD
Scleroderma is a connective tissue disease that involves the hardening and tightening of the skin and connective tissues and can involve the digestive tract, heart, lungs, and kidneys. Patients with scleroderma are considered suboptimal lung transplant candidates due to: Small chest cavities and severe pulmonary hypertension, Esophageal dysmotility and gastroesophageal reflux disease (GERD), Increased risk for renal insufficiency, Extra-pulmonary manifestations. Read more
The final Plenary session of ISHLT2019 included the President’s Debate – a rousing look at Retransplantation – as well as two What’s Hot. What’s New sessions. Read on for the highlights: Read more